Relmada Therapeutics Inc. (RLMD)
Relmada Therapeutics Statistics
Share Statistics
Relmada Therapeutics has 33.19M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 33.19M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 27.84% |
| Shares Floating | 27.81M |
| Failed to Deliver (FTD) Shares | 774 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 1.62M, so 4.89% of the outstanding shares have been sold short.
| Short Interest | 1.62M |
| Short % of Shares Out | 4.89% |
| Short % of Float | 4.96% |
| Short Ratio (days to cover) | 4.39 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -0.47. Relmada Therapeutics's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -0.47 |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.44 |
| P/FCF Ratio | -0.3 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Relmada Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.45, with a Debt / Equity ratio of 0.
| Current Ratio | 4.45 |
| Quick Ratio | 4.45 |
| Debt / Equity | 0 |
| Debt / EBITDA | - |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $0 |
| Employee Count | 17 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -30.57% in the last 52 weeks. The beta is 0.41, so Relmada Therapeutics's price volatility has been higher than the market average.
| Beta | 0.41 |
| 52-Week Price Change | -30.57% |
| 50-Day Moving Average | 0.3 |
| 200-Day Moving Average | 0.59 |
| Relative Strength Index (RSI) | 88.07 |
| Average Volume (20 Days) | 1.17M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | 0 |
| Net Income | 0 |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 3.86M in cash and 0 in debt, giving a net cash position of 3.86M.
| Cash & Cash Equivalents | 3.86M |
| Total Debt | 0 |
| Net Cash | 3.86M |
| Retained Earnings | -640.88M |
| Total Assets | 45.82M |
| Working Capital | 35.5M |
Cash Flow
In the last 12 months, operating cash flow was -51.76M and capital expenditures 0, giving a free cash flow of -51.76M.
| Operating Cash Flow | -51.76M |
| Capital Expenditures | 0 |
| Free Cash Flow | -51.76M |
| FCF Per Share | -1.72 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RLMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RLMD is $1, which is 49.3% higher than the current price. The consensus rating is "Hold".
| Price Target | $1 |
| Price Target Difference | 49.3% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Sep 30, 2019. It was a backward split with a ratio of 1:4.
| Last Split Date | Sep 30, 2019 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | -25.32 |
| Piotroski F-Score | 1 |